Effectiveness and Tolerance of Neoadjuvant Chemotherapy for Treatment of Locally Advanced Gastric Cancer

Abstract

This study aims to assess effectiveness and tolerance with neoadjuvant chemotherapy in patients with locally advanced gastric cancer in the period of 2018-2020. The study used the descriptive cross-sectional method to investigate 70 patients diagnosed with locally advanced gastric cancer, assigned to ECX/ECF or FLOT neoadjuvant chemotherapy regimens at Vietnam National Cancer Hospital. The results show that the partial response rates in the ECX/ECF and FLOT groups were 69.70% and 89.20%, respectively. There was no significant difference in the response level between the two groups (p = 0.716). 78.79% in the ECX/ECF group and 88.56% in the FLOT group underwent surgery. Neutropenia was an adverse event with the highest rate of grades 3 and 4 in both regimens (FLOT regimen was 10.81%, ECX/ECF regimen was 24.24%). There is a statistically significant difference in the incidence of events between the groups with prophylaxis and non-prophylaxis by granulocyte colony-stimulating factor. Taken together, there was no significant difference in the response level between the two groups; regarding the event of neutropenia, it could be controlled by prophylaxis in terms of benefits and risks for each patient.

Keywords:

Gastric cancer, effectiveness, safety, neoadjuvant chemotherapy.

References

[1] International Agency for Research on Cancer Global Cancer Observatory, 2020.
[2] Ministry of Health, Guidelines for the Diagnosis and Treatment of Stomach Cancer, 2020 (in Vietnamese).
[3] K. Liu, G. Li, C. Fan, C. Zhou, J. Li, Adapted Choi response Criteria for Prediction of Clinical Outcome in Locally Advanced Gastric Cancer Patients Following Preoperative Chemotherapy, Acta Radiologica, Vol. 53, No. 2, 2012, pp.127-34, https:// doi.org/10.1258/ar.2011.110273.
[4] D. Cunningham, W. H. Allum, S. P. Stenning,J. N. Thompson, C. J. H. V. Velde, M. Nicolson,J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson,D. B. Smith, R. E. Langley, M. Verma, S. Weeden,Y. J. Chua, MAGIC Trial Participants. Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer, New England Journal of Medicine, Vol. 355, No.1, 2006, pp. 11-20, https://doi.org/10.1056/ NEJMoa055531.
[5] S. E. A. Batran, N. Homann, C. Pauligk,T. O. Goetze, J. Meiler, S. Kasper, H. G. Koppet, et al., FLOT4-AIO Investigators, Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial, Lancet, Vol. 393, No. 10184, 2019, pp. 1948-1957, https://doi.org/ 10.1016/S0140-6736(18)32557-1.
[6] L. Sung, P. C. Nathan, S. M. Alibhai, G. A. Tomlinson, J. Beyene, Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection, Annals of Internal Medicine, Vol. 147, No. 6, 2007, pp. 400-411, https://doi.org/10.7326/0003 - 4819 - 147 - 6-200709180 - 00010.